Literature DB >> 29658924

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection.

Chongfeng Xu1, Junhong Ai2, Qingxun Zhang1, Ting Li3, Xiaorong Wu1, Zhengde Xie4, Ziyuan Duan5.   

Abstract

A number of methods have been described to establish NK/T cell lines from patients with lymphoma or lymphoproliferative syndrome. These methods employed feeder cells, purified NK or T cells with as much as 10 mL of blood, or a high-dose of IL-2. This study presents a new method with a powerful and simple strategy to establish NK and T cell lines by culturing the peripheral blood mononuclear cells (PBMC) with the addition of recombinant human IL-2 (rhIL-2), and uses as little as 2 mL of whole blood. The cells can proliferate quickly in two weeks and be maintained for more than 3 months. With this method, 7 NK or T cell lines have been established with a high success rate. This method is simple, reliable, and applicable to establishing cell lines from more cases of CAEBV or NK/T cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29658924      PMCID: PMC5933274          DOI: 10.3791/56515

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

Review 1.  Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?

Authors:  Hiroshi Kimura
Journal:  Rev Med Virol       Date:  2006 Jul-Aug       Impact factor: 6.989

2.  Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.

Authors:  H Kimura; Y Hoshino; H Kanegane; I Tsuge; T Okamura; K Kawa; T Morishima
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

3.  Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus.

Authors:  H Nagata; A Konno; N Kimura; Y Zhang; M Kimura; A Demachi; T Sekine; K Yamamoto; N Shimizu
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

Review 4.  The chronic mononucleosis syndrome.

Authors:  S E Straus
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

5.  Cloning of Human T and Natural Killer Cells

Authors: 
Journal:  Methods       Date:  1996-06       Impact factor: 3.608

6.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

7.  Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.

Authors:  Yu Zhang; Hiroshi Nagata; Tatsuro Ikeuchi; Hiroyuki Mukai; Michiko K Oyoshi; Ayako Demachi; Tomohiro Morio; Hiroshi Wakiguchi; Nobuhiro Kimura; Norio Shimizu; Kohtaro Yamamoto
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

Review 8.  Progress in understanding and managing natural killer-cell malignancies.

Authors:  Kazuo Oshimi
Journal:  Br J Haematol       Date:  2007-10-03       Impact factor: 6.998

9.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.

Authors:  J F Jones; S Shurin; C Abramowsky; R R Tubbs; C G Sciotto; R Wahl; J Sands; D Gottman; B Z Katz; J Sklar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

Review 10.  Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.

Authors:  Koichi Ohshima; Hiroshi Kimura; Tadashi Yoshino; Chul Woo Kim; Young H Ko; Seung-Suk Lee; Suat-Cheng Peh; John K C Chan
Journal:  Pathol Int       Date:  2008-04       Impact factor: 2.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.